Top 50 Stem Cell Therapy

The startup develops stem cell therapeutics using a proprietary technology platform that regulates the immune system and promotes tissue recovery. This approach enhances the delivery efficiency of treatments while minimizing off-target side effects associated with systemic administration of medications.

Stem Bio develops stem cell therapies and anti-cancer drugs to treat various malignancies and regenerative conditions. The company focuses on harnessing the potential of stem cells to enhance treatment efficacy and improve patient outcomes in oncology.

The startup develops next-generation cell therapies utilizing stem cell biology, immunology, and gene editing to treat cancer and autoimmune diseases. By focusing on T cells and other immune cells, the company provides stem cell-derived medicines that enhance treatment efficacy for patients facing these serious health challenges.

This startup develops platform solutions for cell therapy and regenerative medicine, focusing on induced pluripotent stem cell (iPSC) technologies. Their offerings include rapid iPSC reprogramming, a CRISPR-Cas12b gene-editing platform, and bioinformatics-guided differentiation techniques to support upstream and downstream R&D processes for iPSCs and their derivatives.

The startup develops stem cell therapies derived from human cord blood to treat brain injuries in newborns. Their products target conditions such as oxygen deprivation, inflammation, and hemorrhage, providing timely interventions for infants affected by traumatic brain injuries and related disorders.

The startup develops personalized cell therapies for vascular diseases using a combination of vascular endothelial progenitor cells and mesenchymal stem cells to regenerate blood vessels. This approach provides symptomatic relief for patients requiring interventions such as vascular bypass surgery, stents, and balloon angioplasty.

APstem is developing a patented cell therapy technology utilizing Adult High Plasticity Stem Cells (AHPSCs) derived from human donor blood to treat serious diseases with high regenerative potential. This approach addresses the limitations of current stem cell therapies by offering a safe, allogeneic solution that is cost-effective and efficient to manufacture.

Auragens provides personalized regenerative medicine treatments utilizing umbilical cord-derived mesenchymal stem cells (hUC-MSCs) and exosome therapies. The center offers tailored protocols for orthopedic, autoimmune, cardiovascular, and neurological conditions. They focus on optimizing patient outcomes through advanced in-house cell processing and comprehensive wellness integration.

The startup develops magnetic field equipment that utilizes a targeting system to guide stem cells for cartilage regeneration in patients with knee osteoarthritis. This technology enables precise delivery of magnetic stem cells to the affected joint area, effectively alleviating pain and improving joint function.

Reprogenix develops proprietary stem cell therapies targeting diabetes, utilizing advanced cell injection techniques to restore insulin production. Their lead product, RGB5088, is currently undergoing clinical trials, positioning the company at the forefront of cellular treatments for metabolic disorders.

The startup develops therapeutics that specifically target cancer stem cells, utilizing stem cell-targeted delivery methods to enhance treatment efficacy. Their approach aims to reduce pain and improve the quality of life for cancer patients through translational research in drug development.

The startup develops cell-based therapies utilizing patented induced pluripotent stem cell (iPSC) generation and endothelial cell differentiation technology to treat cardiovascular disease. This approach enables the regeneration of damaged heart tissue, improving recovery outcomes for patients suffering from cardiovascular conditions.

Zephyrm Biotech develops stem cell medications to address degenerative diseases and enhance regenerative therapies. By utilizing advanced stem cell technology, the company aims to improve patient outcomes and reduce the burden of chronic health conditions.

Century Therapeutics develops allogeneic, induced pluripotent stem cell (iPSC)-derived NK and T cell therapies to treat hematological and solid tumor malignancies, as well as autoimmune diseases. Their platform addresses the limitations of existing cell therapies by providing scalable, fit-for-purpose products with enhanced functionalities.

Xellsmart develops clinical-grade induced pluripotent stem cell (iPSC) therapies specifically targeting neurodegenerative diseases, such as Parkinson's disease, for which there are currently no effective treatments. Their approach focuses on providing scalable and cost-effective stem cell solutions to improve patient outcomes in these critical areas of healthcare.

Stem Nova Network supplies USA-made umbilical cord tissue-derived mesenchymal stem cells (UCT-MSCs) and 3D-cultured exosomes, optimized for enhanced bioactivity and therapeutic efficacy. They provide these advanced cellular therapies to clinics and guide individuals to qualified therapy partners, ensuring high viability and ethical sourcing for recovery, immunity, and wellness applications.

The startup develops a stem cell therapy that utilizes organ-intrinsic stem cell separation technology to achieve high-purity cell separation without enzymatic disassembly of organ tissue. This approach aims to enhance regenerative treatment options for patients with intractable diseases by promoting self-replication of living cells.

HELP Therapeutics develops allogeneic off-the-shelf cell therapies using induced pluripotent stem cells (iPSCs) to treat degenerative diseases, particularly in the cardiovascular and nervous systems. Their focus on safe and effective cell products aims to improve patient outcomes in conditions like end-stage heart failure.

This biotechnology company develops stem cell-based therapies for cardiac regeneration. Their focus is on creating targeted stem cell products for myocardial repair, enabling the restoration of damaged heart tissue.

Aspen Neuroscience develops autologous induced pluripotent stem cell (iPSC)-derived neuron replacement therapy specifically for Parkinson's disease, utilizing advanced stem cell biology and genomics. This approach addresses the degeneration of neurons in patients, aiming to restore lost function and improve quality of life.

Develops off-the-shelf hematopoietic stem cell therapies that generate self-renewing, HLA-compatible, and transgene-free blood stem cells from depleted patient or donor cells. This approach eliminates the need for matched donors, providing a scalable solution to treat over 120 severe diseases, including hematological and oncological conditions.

The startup develops stem cell therapeutics utilizing primed stem cells and their exosomes, employing single-cell analysis for precise gene editing. This approach aims to provide effective treatments for incurable diseases by targeting and correcting the underlying genetic causes.

Yuesai Biotech develops cellular therapies utilizing human induced pluripotent stem cells (hiPSCs) to provide treatment options for neurodegenerative diseases and rare disorders. The company employs advanced technologies such as reprogramming, stem cell differentiation, and high-precision gene editing to address significant unmet medical needs in these areas.

Ensoma develops one-time, off-the-shelf, in vivo treatments that utilize advanced hematopoietic stem cell engineering to precisely modify cells within the hematopoietic system. This technology aims to provide durable cures for genetic, immune, and oncological diseases by addressing the limitations of traditional therapies that often require multiple treatments.

MesencHyal-T develops advanced cell therapies for bone regeneration using allogeneic mesenchymal stem cells and hyaluronic acid. Their AI-powered platform optimizes treatment for bone injuries and degenerative conditions, offering scalable, ready-to-use products for improved healing and patient quality of life.

iCamuno Biotherapeutics develops a cell therapy drug using induced pluripotent stem cells (iPSCs) and gene editing technologies to create effective and affordable treatments for cancer patients. The company focuses on somatic cell reprogramming and stem cell differentiation to provide universal access to safe cellular therapies that meet unmet clinical needs.

MIDA Biotech develops personalized induced pluripotent stem (iPS) cells using microfluidic technology to create targeted therapies for neurodegenerative diseases and age-related disorders. The company addresses the need for effective treatments that restore damaged motor and sensory nerves, enhancing patient outcomes in regenerative medicine.

GC Therapeutics utilizes a "plug-and-play" induced pluripotent stem cell (iPSC) programming platform, TFome™, to efficiently generate various cell types for cell therapies. This technology addresses the challenges of scalability and accessibility in cell therapy development, enabling the rapid production of off-the-shelf iPSC-based medicines for gastrointestinal, neurological, and immunological diseases.

Notch Therapeutics develops UNi-T Cells, a universal T cell therapy derived from induced pluripotent stem cells (iPSCs) that provides a standardized, off-the-shelf solution for cancer treatment. This approach eliminates the variability and high costs associated with patient-specific CAR-T therapies, enabling broader patient access to effective cell-based treatments.

The startup utilizes a modified CRISPR system to direct stem cells along specific developmental pathways through precise genetic instruction sets, mimicking embryonic development. This technology enables the scalable production of diverse stem cell types for therapeutic applications across various medical conditions.

Cell BioEngines is a clinical-stage biotech company developing allogeneic, off-the-shelf stem cell therapies as drugs for serious human diseases. The company utilizes a transgene-free "super-donor" stem cell platform designed to reprogram cell fate and function. Their competitive advantage lies in scalable manufacturing of chemically reprogrammed stem cells combined with HLA-guided design for broad patient coverage.

This biotechnology company develops nanomedicine-driven gene and cell therapies for neurological disorders. They program patient stem cells using biomaterials and nanomedicine technologies to create treatments for brain cancer and other neurological conditions.

The startup specializes in cell and gene therapy by sourcing marrow and stem cells from qualified volunteer donors to facilitate research and commercialization of gene therapies. This approach aims to provide cost-effective and timely treatments for life-threatening diseases, enhancing healthcare delivery.

Somagenetix develops lentivirus-transduced stem cell therapies to treat phagocyte-related genetic disorders, including Chronic Granulomatous Disease (CGD). Their one-time treatment approach ensures targeted action within terminally differentiated cells, offering a safe and effective solution for over 50 known genetic conditions.

TreeFrog Therapeutics develops proprietary C-Stem™ technology to produce scalable, high-quality cell therapies, including a lead program targeting Parkinson’s disease. The company addresses the need for effective and safe regenerative medicine by enabling the production of billions of cells in a single batch, facilitating clinical trials and patient access.

Genetix Biotherapeutics develops FDA‑approved ex vivo lentiviral gene‑addition therapies that modify autologous CD34⁺ hematopoietic stem cells to correct the genetic defect in sickle cell disease, β‑thalassemia, and cerebral adrenoleukodystrophy. The single‑administration products are manufactured at GMP scale, distributed globally, and supported by a patient‑services platform that handles insurance, site coordination, and long‑term safety monitoring for up to 15 years. The solution is sold to transplant and specialty hospitals and integrated with standard conditioning regimens and electronic health‑record reporting.

The startup is developing a platform that utilizes small molecule compounds to induce neural stem cells for the treatment of chronic spinal cord injuries. This technology aims to enable clinicians to provide targeted cell therapy, addressing the significant limitations in current treatment options for patients with spinal cord damage.

The startup develops placenta-based therapeutic treatments that utilize growth factors and bioactive molecules to promote tissue repair and modulate immune responses. These therapies aim to reverse the progression of degenerative diseases by enabling the replacement or repair of damaged cells, facilitating functional recovery.

Nuwacell specializes in the research, development, and production of induced pluripotent stem cell (iPSC)-derived therapies for clinical applications. The company addresses the need for effective cell-based treatments in regenerative medicine by providing scalable and reliable cell therapy products.

SingCell offers outsourced contract research organization (CRO) services, including quality control testing and process development, specifically for stem cell therapy and clean meat production. The company addresses the need for reliable manufacturing and analytical capabilities in these emerging industries, ensuring compliance and efficiency in their production processes.

Stemora develops novel cell-based therapies focused on regenerating cartilage for patients suffering from osteoarthritis. The company leverages stem cell innovation to create treatment options aimed at restoring joint mobility. Their work seeks to redefine the standard of care for osteoarthritis management.

IStemRewind offers a proprietary medical device for rapid, enzyme-free stem cell extraction. This technology preserves cell integrity and function, improving the efficiency and efficacy of regenerative medicine treatments.

XJ Biotech specializes in the in vitro production of platelets derived from stem cells, addressing the critical shortage of platelets needed for treating cancer, liver disease, and other hematological conditions. The company also develops targeted therapies for diseases associated with platelet dysfunction, enhancing treatment options for patients with thrombocytopenia and related disorders.

Vita Therapeutics specializes in cell engineering techniques to regenerate damaged tissues and organs, utilizing precise cell manipulation to enhance recovery outcomes for patients with degenerative diseases. The company addresses the limitations of existing therapies by providing targeted cellular interventions that improve tissue repair and functionality.

HiCellTech develops stem cell-based therapies and drug efficacy evaluation platforms specifically targeting cancer stem cells and mesenchymal stem cell treatments. The company addresses the need for effective therapies against metastatic cancer and evaluates drug toxicity, enabling the development of targeted anti-cancer treatments.

Hopstem is a pharmaceutical company specializing in the differentiation of human induced pluripotent stem cells (iPSCs) into neural cells, alongside cell banking and engineering services. This technology addresses the need for reliable and scalable sources of neural cells for research and therapeutic applications in neurodegenerative diseases.

This company develops cell therapies using MSCs to enhance tissue repair and reduce inflammation. Their therapies aim to treat conditions like osteoarthritis and liver disease by leveraging the natural regenerative properties of MSC-secreted factors.

The startup develops genetic cell modification technology to create engineered cell lines that produce therapeutic proteins and enhance immune cell therapies. By utilizing stem cell-derived tissues to express chimeric antigen receptors, the company enables targeted cancer treatment for patients.

Eyestem develops scalable cell replacement therapies using induced pluripotent stem cells to create retinal pigment epithelium (RPE) cells for treating Dry Age-related Macular Degeneration (AMD), a leading cause of blindness in individuals over 60. The company aims to democratize access to these therapies by embedding efficient manufacturing and quality processes, significantly reducing the time to market.

Blue Cell Therapeutics is developing an allogeneic stem cell therapy, known as Blue Cells, that promotes angiogenesis and repairs vascular and neuronal structures to provide a curative treatment for erectile dysfunction. This therapy addresses the unmet medical need for effective solutions in a condition affecting over 30 million men worldwide, with previous trials showing a 73% success rate in restoring erectile function.